2. Signaling Pathways
  3. Cell Cycle/DNA Damage
    Epigenetics
  4. PARP

PARP

poly ADP ribose polymerase

PARP

Related Products

PDF 1.49 MB

PARP is a family of proteins involved in a number of cellular processes involving mainly DNA repair and programmed cell death. The PARP family comprises 17 members. They have all very different structures and functions in the cell. PARP1, PARP2, VPARP (PARP4), Tankyrase-1 and -2 (PARP-5a or TNKS, and PARP-5b or TNKS2) have a confirmed PARP activity. Others include PARP3, PARP6, TIPARP (or PARP7), PARP8, PARP9, PARP10, PARP11, PARP12, PARP14, PARP15, and PARP16. PARP is found in the cell’s nucleus. The main role is to detect and signal single-strand DNA breaks (SSB) to the enzymatic machinery involved in the SSB repair.

PARP Isoform Specific Products:

PARP Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-N17653
    13'-Carboxy-δ-tocopherol
    13'-Carboxy-δ-tocopherol is a metabolite of long-chain vitamin E.13'-Carboxy-δ-tocopherol exhibits antiproliferative properties in cancer cells. 13'-Carboxy-δ-tocopherol activates caspase-3, caspase-9, causes PARP-1 cleavage, reduces mitochondrial membrane potential, increases ROS formation, and drives apoptosis.13'-Carboxy-δ-tocopherol can be used for the research of hepatocellular carcinoma.
    13'-Carboxy-δ-tocopherol
  • HY-181140
    UNPD139734
    		Inhibitor
    UNPD139734 is a CDK-1 inhibitor and PARP-1 inhibitor that forms stable complexes with each target protein. UNPD139734 serves as a lead compound for structural optimization to develop dual-target anticancer agents targeting CDK-1 and PARP-1. UNPD139734 can be used for the research of breast cancer.
    UNPD139734
  • HY-157137
    PARP1-IN-17
    PARP1-IN-17 is a PARP-1 inhibitor (IC50 = 19.24 nM for PARP-1 and = 32.58 nM for PARP-2) and induce apoptosis. PARP1-IN-17 shows excellent anti-proliferative activity.
    PARP1-IN-17
  • HY-161606
    PARP-1/2/7-IN-1
    		Inhibitor
    PARP-1/2/7-IN-1 (compound 86) is a potent inhibitor of PARP-1/2/7, with the IC50 of ＜ 10 nM.
    PARP-1/2/7-IN-1
  • HY-134301A
    8-ET-NAD+ sodium
    8-ET-NAD+ (sodium) is the derivative of NAD+. 8-ET-NAD+ (sodium) can be used in screening of PARP1 gatekeeper mutations. 8-ET-NAD+ (sodium) can be studied in research on cancer.
    8-ET-NAD+ sodium
  • HY-158251
    BIBD-300
    BIBD-300 is a PARP-1 imaging agent with high affinity for PARP-1. BIBD-300 can accurately localize C6 and U87MG tumors, which can be used for research in the diagnosis of breast cancer, prostate cancer, glioma, and liver cancer.
    BIBD-300
  • HY-178972
    PARP1-IN-48
    		Inhibitor
    PARP1-IN-48 (Compound 61) is a highly selective PARP1 (PARP1 IC50 = 3 nM, PARP2 IC50 = 170 nM) inhibitor. PARP1-IN-48 can be used for research on cancer, viral infections, and metabolic conditions.
    PARP1-IN-48
  • HY-RS10065
    Parp3 Rat Pre-designed siRNA Set A
    		Inhibitor

    Parp3 Rat Pre-designed siRNA Set A contains three designed siRNAs for Parp3 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
    Parp3 Rat Pre-designed siRNA Set A
  • HY-175175
    MAPK-IN-5
    		Inhibitor
    MAPK-IN-5 is a potent MAPK inhibitor with an IC50 of 1.35 μM against HeLa cells. MAPK-IN-5 inhibits HeLa cell proliferation by inducing ROS-mediated DNA damage and mitochondrial apoptosis via the MAPK pathway. MAPK-IN-5 significantly inhibits colony formation, reduces the number of live cells, suppresses cell migration, and causes cell cycle arrest in the G2/M phase in HeLa cells. MAPK-IN-5 can be used for the study of cervical cancer.
    MAPK-IN-5
  • HY-168094
    PARP1-IN-30
    		Inhibitor
    PARP1-IN-30 (Compound 3) is a specific and potent PARP1 inhibitor with cytotoxicity. PARP1-IN-30 allows precise inhibition of PARP1 in tumor cells with breast cancer 1 protein (BRCA1) or BRCA2 deficiencies. PARP1-IN-30 is promising for research of cancers.
    PARP1-IN-30
  • HY-148710
    ARTD10/PARP10-IN-2
    		Inhibitor
    ARTD10/PARP10-IN-2 (compound 19) is a potent and non-selective PARP inhibitor, targeting to mono-ADP-ribosyltransferases ARTD10/PARP10 and poly(ADP-ribose) polymerase-1 ARTD1/PARP1 with IC50s of 2.0 μM, and 9.7 μM, respectively.
    ARTD10/PARP10-IN-2
  • HY-174836
    ZINC000081009201
    		Inhibitor
    ZINC000081009201 is a potent poly(ADP-ribose) polymerase 1 (PARP1) inhibitor with an IC50 value of 1.4767 μM. ZINC000081009201 is promising for research of triple-negative breast cancer (TNBC).
    ZINC000081009201
  • HY-181664
    YCH3971
    		Inhibitor
    YCH3971 is a PARP1 inhibitor with a PARP1 IC50 of 7.52 nM and a PARP1 EC50 of 67.75 nM. YCH3971 inhibits the proliferation of BRCA-deficient tumor cells. YCH3971 induces DNA damage, G2/M phase arrest, and caspase-mediated Apoptosis in triple-negative breast cancer cells. YCH3971 can be used for the research of BRCA-deficient tumors.
    YCH3971
  • HY-162172
    PARP7-IN-18
    		Inhibitor
    Parp7-in-18 (Compund 8) is a selective PARP7 inhibitor with an IC50 of 0.11 nM. PARP7-IN-18 exhibits good anticancer activity and pharmacokinetic properties.
    PARP7-IN-18
  • HY-178116
    HER2-IN-23
    		Inhibitor
    HER2-IN-23 is a selective HER2 inhibitor. HER2-IN-23 reduces in total HER2 expression rather than in phosphorylated HER2 (p-HER2). HER2-IN-23 reduces cyclin D1 level and stimulates PARP cleavage. HER2-IN-23 can be used for the study of HER2-positive breast cancer.
    HER2-IN-23
  • HY-155965
    VEGFR/PARP-IN-1
    		Inhibitor
    VEGFR/PARP-IN-1 (Compound 14b) is a VEGFR/PARP dual inhibitor (IC50s: 191 nM and 60.9 nM respectively). VEGFR/PARP-IN-1 inhibits DNA damage repair, induces cell apoptosis, and arrests cell in the G2/M phase. VEGFR/PARP-IN-1 has good antiproliferative efficacy against BRCA wild-type breast cancer cells (IC50: 4.1 and 3.5 μM for MDA-MB-231 and MCF-7 cells). VEGFR/PARP-IN-1 is an antitumor and anti-metastasis agent.
    VEGFR/PARP-IN-1
  • HY-14206
    NU 1085
    		Inhibitor
    NU 1085 is a potent poly(ADP-ribose) polymerase (PARP) inhibitor with a Ki of 6 nM. NU 1085 shows strong cytotoxicity to cancer cells (LC50 = 83-94 μM) and can enhance the anticancer effect of Temozolomide (HY-17364). NU 1085 can be used for the research of cancer, such as lung cancer.
    NU 1085
  • HY-101020R
    Picolinamide (Standard)
    		Inhibitor
    Picolinamide (Standard) is the analytical standard of Picolinamide. This product is intended for research and analytical applications. Picolinamide (2-Picolinamide) is an inhibitor of Poly(ADP-ribose) synthetase of nuclei from rat pancreatic islet cells.
    Picolinamide (Standard)
  • HY-185459
    PCIP-1
    		Inhibitor
    PCIP-1 is a PARP2 inhibitor. PCIP-1 recruits BET proteins to PARP2 to inhibit DNA repair, acts via event-driven pharmacology, and does not inhibit PARP-catalyzed PARylation. PCIP-1 inhibits DNA repair, thereby inducing synthetic lethality in homologous recombination-deficient cancer cells and increasing the sensitivity of PARP1-knockout cells. PCIP-1 can be used in the research of homologous recombination-deficient cancers, T-cell acute lymphoblastic leukemia, and BRCA-mutant cancers.
    PCIP-1
  • HY-161517
    PARP1-IN-20
    		Inhibitor
    PARP1-IN-20 (compound 19A10) is a potent inhibitor of PARP1, with the IC50 of 4.62 nM and has similar low PARP-Trapping effect compared with Veliparib (HY-10129), IC50 (MDA-MB-436) >100 μM.
    PARP1-IN-20
Cat. No. Product Name / Synonyms Application Reactivity
PARP Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.